#ISC25 Closing Main Event
Nine presenters will provide updates on their Late-Breaking Science.
11 a.m.-1:05 p.m. | Friday, Feb. 7 | Main Event Hall
LB37 | Effects of Direct Oral Anticoagulants Versus No Anticoagulation in the Prevention of Stroke in Intracerebral Haemorrhage Survivors With Atrial Fibrillation (PRESTIGE-AF) Trial
Roland Veltkamp, Imperial College London, London, United Kingdom
LB38 | Intra-Arterial Tenecteplase Thrombolysis for Acute LVO After Successful Mechanical Thrombectomy Recanalization (ANGEL-TNK) — A Multicenter, Prospective, Randomized, Open-Label, Blinded Endpoint Trial
Miao Zhongrong, Beijing Tiantan Hospital, Beijing, China
LB39 | The Optimal Dosage of Adjunctive Intra-Arterial Tenecteplase Following Successful Endovascular Thrombectomy in Patients With Large Vessel Occlusion Acute Ischemic Stroke (DATE) Trail
Xianhua Hou, The First Affiliated Hospital, Army Medical University, Chongqing, China
LB40 | Extending the Time Window for Tenecteplase by Effective Reperfusion of Penumbral Tissue in Patients With Large Vessel Occlusion (ETERNAL-LVO): A Multicenter, Prospective, Open-Label, Blinded Endpoint, Controlled, Phase 3, Superiority Trial
Vignan Yogendrakumar, The Ottawa Hospital, Ottawa, ON, Canada
LB41 | Treatment With Intravenous Alteplase in Ischemic Stroke Patients With Onset Time Between 4.5 And 24 Hours
Min Lou, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China
LB42 | Intra-Arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy (PEARL): A Multicenter Randomized Trial
Yamei Tang, Sun Yat-sen Memorial Hospital, Guangzhou, China
LB43 | A Randomized Controlled Trial of Antithrombotic Therapy in Ischemic Stroke Patients With Non-Valvular Atrial Fibrillation and Atherosclerosis: The ATIS-NVAF Trial
Shuhei Okazaki, NHO Osaka National Hospital, Osaka, Japan
LB44 | Liraglutide in Acute Minor Ischemic Stroke or High-Risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus (LAMP): A Randomized Clinical Trial
Huili Zhu, The First Affiliated Hospital of Jinan University, Guangzhou, China
LB45 | BXOS110 for Acute Ischemic Stroke Treatment (BEST): A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial
Yarong Ding, Beijing Tiantan Hospital, Beijing, China
See Online Program Planner for more information.
